3,4-dihydroxyphenylacetic acid (DOPAC) and the rat mesolimbic dopaminergic pathway: drug effects and evidence for somatodendritic mechanisms.

por Beart, P. M., Gundlach, A. L.
Publicado 1980

Blockade by polyamine NMDA antagonists related to ifenprodil of NMDA-induced synthesis of cyclic GMP, increases in calcium and cytotoxicity in cultured neurones.

por Beart, P M, Schousboe, A, Frandsen, A
Publicado 1995

Flavonoids: some of the wisdom of sage?

por Johnston, G A R, Beart, P M
Publicado 2004

Transporters for L-glutamate: An update on their molecular pharmacology and pathological involvement

por Beart, P M, O'Shea, R D
Publicado 2006

Evidence for dopamine receptors on GABA-releasing nerve terminals in rat nucleus accumbens [proceedings]

por Beart, P. M., Kuppers, D., Louis, W. J.
Publicado 1980

Neuropharmacology of addiction—setting the scene

por Lawrence, A J, Beart, P M, Kalivas, P W
Publicado 2008

Mitochondrial pharmacology: energy, injury and beyond

por Davidson, S M, Lopaschuk, G D, Spedding, M, Beart, P M
Publicado 2014

Effect of acute alpha-methyldopa administration on catecholamine levels in anterior hypothalamic-preoptic and medullary nuclei in rat brain [proceedings]

por Conway, E L, Jarrott, B, Louis, W J, Beart, P M
Publicado 1978

Therapeutics for dementia and Alzheimer's disease: New directions for precision medicine

por Duce, J.A., Zhu, X., Jacobson, L.H., Beart, P.M.
Publicado en Br J Pharmacol (2019)

A comparison between the in vivo and in vitro activity of five potent and competitive NMDA antagonists.

por Lodge, D., Davies, S. N., Jones, M. G., Millar, J., Manallack, D. T., Ornstein, P. L., Verberne, A. J., Young, N., Beart, P. M.
Publicado 1988